Recent Investment Analysts’ Ratings Updates for Integra Lifesciences (IART)

A number of firms have modified their ratings and price targets on shares of Integra Lifesciences (NASDAQ: IART) recently:

  • 8/1/2019 – Integra Lifesciences was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/27/2019 – Integra Lifesciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/26/2019 – Integra Lifesciences was given a new $66.00 price target on by analysts at Royal Bank of Canada. They now have a “hold” rating on the stock.
  • 7/25/2019 – Integra Lifesciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $70.00. They now have an “outperform” rating on the stock.
  • 7/25/2019 – Integra Lifesciences had its price target raised by analysts at Wells Fargo & Co from $55.00 to $68.00. They now have a “market perform” rating on the stock.
  • 7/25/2019 – Integra Lifesciences had its price target raised by analysts at JMP Securities to $75.00.
  • 7/24/2019 – Integra Lifesciences was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/24/2019 – Integra Lifesciences was given a new $70.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 7/9/2019 – Integra Lifesciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/2/2019 – Integra Lifesciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/20/2019 – Integra Lifesciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $56.00 price target on the stock. According to Zacks, “Integra LifeSciences exited the first quarter of 2019 on a mixed note with better-than-expected earnings and a revenue miss. However, organic revenue growth was encouraging and was in line with the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in mid-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.  Integra LifeSciences underperformed its sector in the past three months.”

Shares of NASDAQ IART traded down $0.80 during midday trading on Thursday, reaching $60.09. The company had a trading volume of 7,654 shares, compared to its average volume of 414,751. The company’s 50-day moving average is $58.16. The company has a market cap of $5.30 billion, a PE ratio of 24.83, a P/E/G ratio of 1.94 and a beta of 1.09. Integra Lifesciences Holdings Corp has a 1 year low of $42.14 and a 1 year high of $66.41. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.08. The business had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $0.60 earnings per share. Equities analysts expect that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current year.

In other news, VP Daniel L. Reuvers sold 5,000 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the vice president now owns 35,392 shares in the company, valued at $2,123,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Kenneth Burhop sold 6,656 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $63.98, for a total transaction of $425,850.88. Following the completion of the sale, the vice president now owns 15,921 shares in the company, valued at approximately $1,018,625.58. The disclosure for this sale can be found here. Insiders sold 21,186 shares of company stock worth $1,277,791 in the last quarter. Company insiders own 4.50% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Municipal Employees Retirement System of Michigan lifted its stake in shares of Integra Lifesciences by 1.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock worth $731,000 after buying an additional 190 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Integra Lifesciences by 5.9% during the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after purchasing an additional 242 shares during the period. LPL Financial LLC raised its stake in Integra Lifesciences by 4.4% during the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after purchasing an additional 242 shares during the period. Advisor Group Inc. raised its stake in Integra Lifesciences by 0.9% during the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock worth $1,719,000 after purchasing an additional 282 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its position in shares of Integra Lifesciences by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 28,654 shares of the life sciences company’s stock valued at $1,600,000 after acquiring an additional 404 shares during the last quarter. Institutional investors own 82.97% of the company’s stock.

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: What is the return on assets (ROA) ratio?

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.